CYP2C19 and depressive disorder: In another study of 227 patients with depressive disorders, Hall-Flavin et al. [52] analyzed various CYP2C19 polymorphisms (*1, *2, *3, *4, *5, *6, *7, and *8) and evaluated differences between patients with treatment guided and not guided by pharmacogenetic tests.